Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Urol Clin North Am. 2012 Nov;39(4):547-60. doi: 10.1016/j.ucl.2012.07.010.
Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.
抗血管生成治疗在实体瘤的治疗中取得了成功。已经有几种策略被用于靶向前列腺癌中的血管生成。这些策略包括通过单克隆抗体或针对下游信号效应通路的小分子抑制剂阻断促血管生成因子，或使用具有免疫调节作用的药物。这篇综述检查了肿瘤血管生成的一般概念，以及使用这些药物和其他新型生物制剂治疗前列腺癌的关键临床试验。具有合理试验设计和联合治疗方法的靶向血管生成治疗仍然是前列腺癌有前途的治疗策略。
